长链非编码 RNA MIAT 在肾透明细胞癌中的表达情况和预后意义

目的 探讨长链非编码RNAMIAT在肾透明细胞癌中的表达情况及与患者临床指标的相关性，分析其作为肾透明细胞癌分子标记物的可能性。方法 通过荧光定量PCR方法 检测MIAT在40例肾透明细胞癌组织和40例癌旁正常组织中的表达情况，同时结合TCGA数据库分析MIAT表达水平与肾透明细胞癌患者临床指标和预后的关系。结果 MIAT在肾透明细胞癌组织中的表达明显高于癌旁正常组织，在肾癌细胞系中的表达明显高于正常肾小管上皮细胞，差异均具有统计学意义（P<0.05）。TCGA数据库资料分析表明，MIAT表达水平与肾癌患者T分期（P<0.001）、M分期呈正相关（P<0.05）。Kaplan-Meier生存分析表明，高表达MIAT的肾癌患者总体生存时间明显低于低表达MIAT的肾癌患者（Log-rankP<0.05）。结论 MIAT在肾透明细胞癌组织和肾癌细胞系中高表达，有可能成为肾透明细胞癌的分子标记物。

The expression and prognostic significance of lncRNA MIAT in clear cell renal cell carcinoma

Objective To explore the expression and prognostic significance of lncRNA MIAT in clear cell renal cell carcinoma, and evaluate its possibility to be a biomarker of clear cell renal cell carcinoma. Methods The expression of MIAT in clear cell renal cell carcinoma and normal tissues were detected by qRT-PCR. The clinical significance and prognostic value of MIAT in clear cell renal cell carcinoma was analyzed using TCGA data. Results The expression of MIAT in clear cell renal cell carcinoma tissues was significantly higher than in normal tissues. The expression of MIAT in renal cancer cells was significantly higher than in HK-2. The expression of MIAT was positively associated with T stage （P<0.001） and M stage （P=0.03）. Meanwhile, patients with higher MIAT expression had a shorter survival time than patients with lower MIAT expression. Conclusion LncRNA MIAT was overexpressed in clear cell renal cell carcinoma tissues and renal cancer cells, and might be a biomarker for clear cell renal cell carcinoma.